Celiac Disease
Conditions
Brief summary
A randomized, double-blind, placebo-controlled, two treatment, parallel group study to investigate the effects of RO5459072, a cathepsin S inhibitor, on the immune response to a gluten challenge in volunteers with celiac disease. Volunteers with previously diagnosed celiac disease will be randomized to receive either 100 milligrams (mg) RO5459072 or placebo twice daily with food for 28 days (Days 1 to 28).
Interventions
DRUGPlacebo
With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
DRUGRO5459072
With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Volunteers with a biopsy confirmed diagnosis of celiac disease * Human leukocyte antigen (HLA) serotype DQ 2.5 and HLA-DQ 8 haplotypes * Maintaining a gluten-free diet for at least one year. Compliance will be assessed by serology, compatible responses to a self-reported assessment of gluten-free diet adherence and the absence of typical celiac disease symptoms * Able to participate and to comply with the study restrictions including the requirements of the gluten challenge
Exclusion criteria
* A diagnosis of non-celiac gluten sensitivity * A personal history of food intolerance other than to gluten, or diagnosis of galactosemia, lactose, galactose or fructose intolerance * A personal history of severe acute symptomatic reaction to sporadic gluten ingestion * A diagnosis of refractory celiac disease or presence of severe complications of celiac disease * Diagnosed or suspected immunoglobulin A (IgA) deficiency * Acute inflammatory bowel disease (ulcerative colitis, Crohn's disease), gastrointestinal obstruction or sub-occlusive syndromes, digestive perforation or risk of digestive perforation, painful abdominal syndromes of undetermined cause * A history of stomach or intestinal surgery or resection. Appendectomy and hernia repair are acceptable * Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple allergies (non-active hay fever is acceptable) * Immunocompromised or with reduced immune function considered to be clinically significant by the Investigator * Immunization within 30 days before the screening visit or planning vaccination during the study * Women who are pregnant or lactating, or who are of child-bearing potential and do not agree to comply with requirements for contraceptive use. Men who do not agree to comply with requirements for contraceptive use and restrictions on sperm donation * Participation in an investigational drug or device study within the three months preceding the screening visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Numbers of Participants who are Responders to the Gluten Challenge, Defined as Participants with an Increase in Number of Gliadin Specific T-cells Above Assay-Specific Thresholds | Day 13 and Day 29 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with an Increase in Antibody Titers (Anti-Tissue Transglutaminase [anti-tTG] Immunoglobulin A [IgA] and Immunoglobulin G [IgG] and Anti-Deamidated Gliadin Peptide (anti-DPG) IgA), as Determined Using Enzyme Immunoassay Methods | Screening, Day 7, Day 13, Day 21, Day 29 and Day 35 (Follow up) |
| Lactulose to Mannitol Ratio (LMR), Determined by Urine Concentrations of Lactulose and Mannitol | Day 7: 1 hour (hr) pre-dose to 1 hr post-dose, 1 hr to 3 hr post-dose, 3 hr to 5 hr post-dose and Day 21: 1 hr pre-dose to 1 hr post-dose, 1 to 3 hr post-dose, 3 hr to 5 hr post-dose |
| Change from Baseline in Number of Circulating White Blood Cells | Day 1 (Baseline), Day 7, Day 13, Day 21, and Day 29 |
| Change from Baseline in Concentrations of the 10 kilodalton (kDa) Cluster of Differentiation 74 (CD74) Intermediate (Fragment p10) in B Cells | Day 1: pre-dose (=Baseline [BL]) and 4 hours (h) post-dose, Day 7: pre-dose and 4 h post-dose, Day 21: pre-dose and 4 h post-dose |
| Percentage of Participants with Adverse Events (AEs) | Up to Day 35 |
| Change from Baseline in Concentrations of Cystatin C Biomarker | Day 1 (Baseline), Day 7, Day 13, Day 21 and Day 29 |
| Maximum Response (Emax ) in p10 upon Cathepsin S Inhibition Ex vivo | Day 1: pre-dose |
| Concentration of RO5459072 that Gives Half-maximal Response (EC50) in Ex Vivo p10 Stimulation Assay | Day 1: pre-dose |
| Change from Baseline in 4Beta-hydrocholesterol Concentration | Day 1 (Baseline), Day 7, Day 13, Day 21 and Day 29 |
| Change from Baseline in Concentrations of Cathepsin S Mass Biomarker | Day 1 (Baseline), Day 7, Day 13, Day 21 and Day 29 |
Countries
United Kingdom
Outcome results
None listed